Open AccessCefiderocol for the Treatment of Adult and Pediatric Patients With Cystic Fibrosis and Achromobacter xylosoxidans Infections
Author(s) -
Nathaniel Warner,
Luther A. Bartelt,
Anne Lachiewicz,
Kathleen Tompkins,
Melissa B. Miller,
Kevin Alby,
Melissa Jones,
Amy Carr,
José Alexander,
Andrew B. Gainey,
Robert Daniels,
AnnaKathryn Burch,
David E. Brown,
Michael J. Brownstein,
Faiqa Cheema,
Kristin E Linder,
Ryan K. Shields,
Sarah Longworth,
David van Duin
Publication year - 2020
Publication title -
clinical infectious diseases/clinical infectious diseases (online. university of chicago. press)
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.44
H-Index - 336
eISSN - 1537-6591
pISSN - 1058-4838
DOI - 10.1093/cid/ciaa1847
Subject(s) - achromobacter xylosoxidans , cystic fibrosis , medicine , achromobacter , intensive care medicine , pseudomonas , bacteria , biology , genetics
Treatment options for Achromobacter xylosoxidans are limited. Eight cystic fibrosis patients with A. xylosoxidans were treated with 12 cefiderocol courses. Pretreatment in vitro resistance was seen in 3 of 8 cases. Clinical response occurred after 11 of 12 treatment courses. However, microbiologic relapse was observed after 11 of 12 treatment courses, notably without emergence of resistance.